Literature DB >> 30811781

Intravascular lithotripsy-assisted Impella insertion: A case report.

Robert F Riley1, John D Corl1, Dean J Kereiakes1.   

Abstract

Coronary and peripheral arterial calcification increases the complexity of percutaneous treatment strategies in both coronary and peripheral interventions. The first use of intravascular lithotripsy (IVL) using the Shockwave IVL device (Shockwave Medical Inc) in femoropopliteal arteries for modification of calcified plaque was recently described. We present a case illustrating use of the device to deliver a 14 French sheath for delivery of an Impella mechanical circulatory device prior to high-risk percutaneous coronary intervention (PCI). This case illustrates that IVL may be used to facilitate a broadening array of procedures in the catheterization laboratory, including the delivery of large bore sheathes.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  complex PCI; mechanical circulatory support; new devices; peripheral arterial disease

Mesh:

Year:  2019        PMID: 30811781     DOI: 10.1002/ccd.28168

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  3 in total

Review 1.  Role of Lithotripsy for Small Calcified Iliacs in the Era of Big Devices.

Authors:  Francesca Ristalli; Carlotta Sorini Dini; Miroslava Stolcova; Giulia Nardi; Serafina Valente; Francesco Meucci; Carlo Di Mario
Journal:  Curr Cardiol Rep       Date:  2019-11-22       Impact factor: 2.931

2.  Subclavian Impella 5.0 to the rescue in a non-ST elevation myocardial infarction patient requiring unprotected left main rotablation: A case report.

Authors:  Vasileios Panoulas; María Monteagudo-Vela; Konstantinos Kalogeras; Andre Simon
Journal:  World J Cardiol       Date:  2020-04-26

3.  Intravascular lithotripsy to treat an ostial left main coronary artery stenosis due to porcelain aorta in a patient with congenital high-density lipoprotein deficiency.

Authors:  Murat Çimci; Juan F Iglesias; Christoph Huber; Francois Mach; Marco Roffi
Journal:  Anatol J Cardiol       Date:  2020-11       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.